MedPath

Roche Holding AG

Roche Holding AG logo
🇨🇭Switzerland
Ownership
Public
Established
1896-01-15
Employees
103.6K
Market Cap
$270.5B
Website
http://www.roche.com
Clinical Trials
Related News

An Observational Study of Avastin (Bevacizumab) in Patients With Glioblastoma Multiforme in First or Second Relapse

Completed
Conditions
Glioblastoma Multiforme
First Posted Date
2012-06-13
Last Posted Date
2018-02-28
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
20
Registration Number
NCT01618747

A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)

Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Tocilizumab
First Posted Date
2012-06-12
Last Posted Date
2016-12-01
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
50
Registration Number
NCT01617005

A Study to Compare the Bioavailability of Copegus and Vilona® in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: ribavirin [Copegus]
Drug: ribavirin [Vilona]
First Posted Date
2012-06-08
Last Posted Date
2016-11-01
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
40
Registration Number
NCT01615393

A Study of Aleglitazar in Combination With Oral Contraceptive Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: Microgynon®
Drug: Aleglitazar
Drug: Placebo
First Posted Date
2012-06-08
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
18
Registration Number
NCT01615354

An Observational Study of RoActemra/Actemra (Tocilizumab) in Rheumatoid Arthritis Patients

Completed
Conditions
Rheumatoid Arthritis
First Posted Date
2012-06-08
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
60
Registration Number
NCT01615419

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With Tocilizumab (RoActemra/Actemra)

Completed
Conditions
Rheumatoid Arthritis
Interventions
Other: No intervention
First Posted Date
2012-06-07
Last Posted Date
2016-10-04
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
200
Registration Number
NCT01613378

An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis

Completed
Conditions
Rheumatoid Arthritis
Interventions
Biological: Rituximab
First Posted Date
2012-06-06
Last Posted Date
2016-10-24
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
135
Registration Number
NCT01613027

A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: RO4917838
Drug: Moxifloxacin
Drug: RO4917838 placebo
First Posted Date
2012-06-06
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
169
Registration Number
NCT01613040

A Relative Bioavailability Study of Setrobuvir Tablet Formulation Versus Reference Setrobuvir Capsule Formulation in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: setrobuvir
First Posted Date
2012-06-05
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
40
Registration Number
NCT01612143

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION)

Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: tocilizumab [RoActemra/Actemra]
First Posted Date
2012-06-04
Last Posted Date
2014-07-10
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
121
Registration Number
NCT01610791
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy